Pfenex (NYSEAMERICAN:PFNX) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.13, MarketWatch Earnings reports. The company had revenue of $10.36 million during the quarter, compared to analyst estimates of $5.63 million.
Shares of NYSEAMERICAN PFNX traded up $0.51 during trading on Friday, reaching $6.29. The company had a trading volume of 381,383 shares, compared to its average volume of 147,056. Pfenex has a twelve month low of $3.13 and a twelve month high of $8.42.
A number of research firms have recently weighed in on PFNX. William Blair reissued a “buy” rating on shares of Pfenex in a report on Tuesday, April 2nd. Zacks Investment Research raised Pfenex from a “hold” rating to a “buy” rating and set a $5.50 price target for the company in a report on Friday, March 15th. Finally, Wedbush reissued an “outperform” rating on shares of Pfenex in a report on Thursday, March 7th.
TRADEMARK VIOLATION NOTICE: This piece was originally published by WKRB News and is the sole property of of WKRB News. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.wkrb13.com/2019/05/11/pfenex-pfnx-announces-quarterly-earnings-results-beats-estimates-by-0-13-eps.html.
Pfenex Company Profile
Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study.
Featured Story: What are the benefits of investing in REITs?
Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.